Florida Doc Loses DEA License Over Sketchy Pill Prescriptions Bust
Published Date: 7/25/2025
Notice
Summary
Dr. Taha Dias from Florida lost his DEA registration because he gave out controlled substance prescriptions in ways that broke the law between 2022 and 2023. Since he didn’t ask for a hearing, the DEA officially revoked his license, meaning he can’t prescribe these drugs anymore. This decision protects the public and took effect after the government’s final review in early 2025.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — No Controlled Drugs
The DEA revoked Taha Dias, M.D.'s Certificate of Registration No. BD9971208, effective August 25, 2025. The Order says he can no longer prescribe controlled substances and that any pending applications to renew, modify, or obtain DEA registration in Florida are denied.
Default Admission for Failing to Seek Hearing
The record shows Dr. Dias did not request a hearing and was deemed in default under 21 CFR 1301.43; that default admitted the OSC's factual allegations. The Agency found he issued at least 18 prescriptions lacking a legitimate medical purpose between July 5, 2022 and December 4, 2023, including promethazine with codeine, oxycodone, and alprazolam.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-14076 — Committee on Equal Opportunities in Science & Engineering; Cancellation of Meeting
Heads up! The National Science Foundation’s Committee on Equal Opportunities in Science & Engineering has canceled their meeting that was set for October 30, 2025. If you were planning to join or follow their updates, no worries—just mark your calendar and stay tuned for future announcements. This change won’t affect any funding or deadlines right now.
Next: 2025-14078 — Federal Secure Cloud Advisory Committee Notification of Upcoming Meeting
The Federal Secure Cloud Advisory Committee is holding a public meeting soon, and anyone interested can join or share their thoughts. This meeting affects government cloud security plans and could shape future tech rules. No costs or deadlines are announced yet, but staying tuned is a smart move!